Comparing Outcomes for Rare Primary Hepatic Tumors after Liver Transplantation

Nhu Thao T Nguyen*, Theresa R Harring1, Jacfranz J Guiteau1, Ron T Cotton1, Ismael Salas de Armas1, Hao Liu2, John A Goss1 and Christine A O'Mahony1

1Division of Abdominal Transplantation and Hepatobiliary Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1709 Dryden Road Suite 1500, Houston, Texas 77030
2Division of Biostatistics, Dan L. Duncan Cancer Center, Department of Medicine, Section of Hematology/Oncology, Baylor College of Medicine, One Baylor Plaza, 450A, Houston, Texas 77030

Abstract

Aim: Liver transplantations (LT) have proven to be a successful treatment for many tumors of the liver. The goal of this study was to evaluate the outcomes of liver transplantations in patients with primary liver tumors with a focus on rarer malignancies.

Methods: The UNOS database catalogues all adult patients who underwent LT for a primary liver tumor from 1992-2008. Of the 73,231 liver transplantations, 5,682 patients with liver tumors were identified and categorized by indication for LT: hepatocellular carcinoma (HCC, n=5272), hepatic epithelioid hemangioendothelioma (HEH, n=85), cholangiocarcinoma (n=249), sarcomas (n=11) and combined HCC-Cholangiocarcinomas (HCC-CC, n=12). Survivals were calculated using Kaplan-Meier and log rank tests.

Results: 5,629 patients received LT for solid liver tumors. HCC patients and their allografts survived longer than those transplanted for cholangiocarcinomas (p=0.001, 0.002) or for HCC-CC (p=0.025, 0.004). Overall survival rates of HCC patients were 86.4%, 71.3%, and 61.2% at 1, 3 and 5 years, respectively. Cholangiocarcinoma patients had survival rates of 79.7%, 60.3% and 45.5% at 1-, 3- and 5-years from transplant. HCC-CC patients had the worst overall survival of 72.9%, 39.1% and 39.1% at 1, 3 and 5 years. Allograft survival in HCC-CC patients was comparatively low, averaging 65.6%, 35.2% and 0% at 1-, 3- and 5-years. HEH patients and their allografts survived the longest with overall survival of 83.9%, 77.8% and 73.5% at 1, 3 and 5 years, respectively, and allograft survival at 76.8%, 69.8% and 64.9%.

Conclusion: Our data reveals overall survival was significantly better in HEH patients when compared to HCC, cholangiocarcinoma and HCC-CC patients after LT. In fact, HCC-CC patients fared the worst, both in patient and allograft survival, as compared to HCC and HEH. Results of cholangiocarcinoma patients show worse survival after LT compared to HCC and HEH, though recent evidence suggests adjuvant therapy will change outcomes for the future. Our findings suggest transplantation for HCC-CC may not be sufficient treatment. Other forms of adjuvant and neoadjuvant therapy may be indicated, warranting further research.

Keywords: Liver transplantation; Primary liver malignancy; Survival analysis; Combined hepatocellular carcinoma-cholangiocarcinoma; Hepatic epithelioid hemangioendothelioma; Soft tissue sarcoma

Abbreviations: UNOS: United Network for Organ Sharing; LT: Liver Transplantation; OLT: Orthotopic Liver Transplantation; MELD: Model for End-Stage Liver Disease; HCC: Hepatocellular Carcinoma; HB: Hepatoblastoma, HEH: Hepatic Epithelioid Hemangioendothelioma, NET: Neuroendocrine tumors; HCC-CC: Combined Hepatocellular Carcinoma and Cholangiocarcinoma; Lrx: Liver resection

Introduction

Liver transplantation (LT) serves as a critical treatment modality for end-stage liver disease and a certain subset of hepatic tumors. For hepatic tumors, its role has evolved to include neoadjuvant chemotherapy and radiotherapy for many primary liver cancers with improved outcomes over the years [1]. LT has proven to be a well-established and successful treatment for hepatocellular carcinoma (HCC), the predominant primary cancer of the liver worldwide [2-4]. Cholangiocarcinoma is another primary liver tumor, second greatest in frequency though with much poorer long-term prognosis [1,5,6]. The outcomes of these patients after LT are well documented; [6-9] however, less data exists in regards to outcomes of transplantations for rarer malignancies of the liver, such as hepatic epithelioid hemangioendothelioma (HEH) [10,11] or combined hepatocellular carcinoma-cholangiocarcinomas (HCC-CC) [12]. Frequencies of these tumors vary greatly according to world region. Little data on these malignancies come from North America, where the incidence of these rarer tumors is lower. The infrequency of these tumors often makes single-center experiences limited in both scope and power of study. The aim of this study is to further characterize the outcomes of liver transplantations performed for primary liver tumors on a national level.

Primary liver tumors comprise 4% of cancer diagnoses globally. HCC is diagnosed in 4.8 per 100,000 people annually, whereas sarcomas and HEH are found in <0.1 per 100,000 people in the general population [13]. Cholangiocarcinoma occurs in 2.5 per 100,000 people. Combined HCC-CC has been reported to occur in as few as 1% to as many as 14.3% of the population depending on locale [14,15]. It becomes more evident how such infrequent tumors with varying degrees of predictability in clinical course can be difficult to characterize and...
treat with a standardized therapeutic approach [1,11]. Currently, LT yields excellent results for patients with HCC and remains a standard indication for OLT in selected patients [13,16]. Results for HEH are increasingly reported to be satisfactory as well for cases detected earlier in the clinical course with adjuvant therapy, though has yet to be proven as a durable treatment from lack of larger case series [1,10,11,13,17,18].

HCC-CC, on the other hand, offers poorer prognosis in recent review [19,20]. This study compared and contrast the outcomes of patients with HCC, HEH, cholangiocarcinoma, sarcomas and combined HCC-CC who underwent a LT in the United States in the past 16 years to gain a better general understanding of our progress in the field of primary liver tumors and the role of LT as treatment.

Methods

LT cases were reviewed in the retrospectively maintained and comprehensive United Network Organ Sharing/Organ Procurement Transplantation Network (UNOS/OPTN) dataset which catalogues all transplantations in the United States to compare and contrast the survival experiences between the tumor types. The UNOS/OPTN database was used to select for all 73,231 adult (≥ 18 years old) patients who underwent LT between 1992-2008. Of those, patients with a primary liver tumor were identified in 5,629 cases. These 5,629 patients were divided into pre-operative indications for OLT and the categories of tumor types used for comparisons were hepatocellular carcinoma (HCC, n=5272), hepatic epithelioid hemangioendothelioma (HEH, n=85), cholangiocarcinoma (n=249), sarcomas (n=11) and combined HCC-CC (n=12). Exclusion criteria included Status-1 patients, multiorgan recipients and retransplanted patients.

Time-to-event data were obtained from this database to estimate post-OLT survival. Specifically, the time variable was calculated as the length of time between transplantation and either death or last known follow-up. An observation was censored if the individual was alive at the last known follow-up. Patient and allograft survival rates were determined using the Kaplan-Meier test and the log-rank test. These

<table>
<thead>
<tr>
<th>Solid Tumor Types</th>
<th>1-Year Survival (Std. Error)</th>
<th>3-Year Survival (Std. Error)</th>
<th>5-Year Survival (Std. Error)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular Carcinoma (5272)</td>
<td>86.4 (0.5)</td>
<td>71.3 (0.8)</td>
<td>61.2 (1.1)</td>
</tr>
<tr>
<td>Hepatic Epithelioid Hemangioendothelioma (85)</td>
<td>83.9 (4.3)</td>
<td>77.7 (5.0)</td>
<td>73.5 (5.5)</td>
</tr>
<tr>
<td>Cholangiocarcinoma (249)</td>
<td>76.8 (7.8)</td>
<td>60.3 (3.9)</td>
<td>65.5 (4.8)</td>
</tr>
<tr>
<td>Sarcoma (11)</td>
<td>78.8 (13.4)</td>
<td>45.0 (16.6)</td>
<td>45.0 (16.6)</td>
</tr>
<tr>
<td>Combined HCC-CC (12)</td>
<td>72.9 (13.5)</td>
<td>39.1 (16.3)</td>
<td>39.1 (16.3)</td>
</tr>
</tbody>
</table>

Table 1: Overall Patient Survival Time between Primary Liver Tumor Types.

<table>
<thead>
<tr>
<th>Solid Tumor Types</th>
<th>Hepatocellular Carcinoma</th>
<th>Hepatic Epithelioid Hemangioendothelioma</th>
<th>Cholangiocarcinoma</th>
<th>Sarcoma</th>
<th>Combined HCC-CC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Significance (p≤0.05)</td>
<td>.017</td>
<td>.001</td>
<td>.001</td>
<td>.993</td>
<td>.025</td>
</tr>
<tr>
<td>Hepatocellular Carcinoma</td>
<td>.017</td>
<td>.001</td>
<td>.001</td>
<td>.993</td>
<td>.025</td>
</tr>
<tr>
<td>Hepatic Epithelioid Hemangioendothelioma</td>
<td>.017</td>
<td>.001</td>
<td>.001</td>
<td>.993</td>
<td>.025</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>.001</td>
<td>.001</td>
<td>.001</td>
<td>.993</td>
<td>.025</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>.993</td>
<td>.245</td>
<td>.758</td>
<td>.843</td>
<td>.843</td>
</tr>
<tr>
<td>Combined HCC-CC</td>
<td>.025</td>
<td>.016</td>
<td>.321</td>
<td>.843</td>
<td>.843</td>
</tr>
</tbody>
</table>

Table 2: Pairwise Comparisons of Patient Survival between Solid Tumor Types.

<table>
<thead>
<tr>
<th>Solid Tumor Types</th>
<th>1-Year Survival (Std. Error)</th>
<th>3-Year Survival (Std. Error)</th>
<th>5-Year Survival (Std. Error)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular Carcinoma (5272)</td>
<td>82.7 (0.6)</td>
<td>67.3 (0.8)</td>
<td>57.5 (1.0)</td>
</tr>
<tr>
<td>Hepatic Epithelioid Hemangioendothelioma (85)</td>
<td>76.8 (4.7)</td>
<td>69.6 (5.2)</td>
<td>64.3 (5.7)</td>
</tr>
<tr>
<td>Cholangiocarcinoma (249)</td>
<td>76.3 (2.9)</td>
<td>57.2 (3.6)</td>
<td>43.2 (4.6)</td>
</tr>
<tr>
<td>Sarcoma (11)</td>
<td>71.6 (1.4)</td>
<td>40.9 (15.6)</td>
<td>40.9 (15.6)</td>
</tr>
<tr>
<td>Combined HCC-CC (12)</td>
<td>65.6 (14.0)</td>
<td>35.2 (15.2)</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 3: Allograft Survival Time between Primary Liver Tumor Types.
trend is statistically significant when comparing overall patient survival to all other tumor types except hepatic sarcomas. Sarcomas trended below HCC, HEH and cholangiocarcinomas, but never reached significance when compared to any other tumor type. Sarcoma patients had patient survivals of 78.8%, 45.0% and 45.0% and allograft survivals of 71.6%, 40.9% and 40.9% at 1-, 3- and 5-years, respectively.

HCC-CC patients had the worst overall survival of 72.9%, 39.1% and 39.1% at 1, 3 and 5 years, significantly worse when compared to HCC and HEH patients. Furthermore, graft survival in HCC-CC patients was comparatively low, at 65.6%, 35.2% and 0% at 1-, 3- and 5-years. Tables 2 and 4 illustrate the significance of overall patient and allograft survival.

Patient survival experience did not become dramatically different between the 5 groups until after the first year after transplantation. HCC patients had the best patient survival in the first year, with a survival experience significantly higher than that of cholangiocarcinoma and combined HCC-CC patients (Table 2); HEH patients had better long-term survivals than HCC by 5 years post-transplantation (p=0.017) though this difference was not significant when comparing allograft survival of the two patient groups (NS, p=0.104).

To further characterize the outcome of HCC-CC patients, we then compared this group to all other LT patients who received an allograft for a solid tumor type. In this comparison, HCC-CC patients were found to do significantly worse than all other solid tumor types and their patients, both in regards to overall patient survival, and also in terms of allograft survival (Figure 3) (p=0.029, p=0.005) reaffirming the poor outcome of this patient subgroup when compared to patients with other tumor types (Table 5).

**Discussion**

Outcomes after LT have improved with advances in immunosuppression, perioperative care, surgical technique and patient selection. Characterizing outcomes helps to reflect on the current system and find opportunities to improve. HCC is the most common primary tumor of the liver and the most common tumor to be transplanted [3,21]. Currently, HCC survival after LT at 5-years approximates 55-70%, significantly improving with the introduction of Milan criteria to organ allocation in 2002 [22-24]. While this study focuses on rare primary malignancies of the liver, the results are compared to the outcomes of HCC patients after LT as the most commonly transplanted malignancy of the liver, accounting for a quarter of all liver transplantations in the US [24].

When comparing the survival experiences of primary liver tumor patients treated with LT in the past 16 years, the data reveals overall survival was significantly better in HEH patients when compared to HCC, cholangiocarcinoma and combined HCC-CC patients.

A review of the recent literature on primary malignant HEH by Mehrabi et al. collected information on 286 patients for whom treatment data was reported, and presented survival outcomes stratified by clinical or surgical management. Liver resection patients collected in this review had survivals of 100% and 75% at 1- and 5-years. Patients who had no treatment had calculated survivals at 1- and 5-years of 39.3% and 4.5%, respectively, compared to those with transplanted livers, who had 96% and 54.5% survivals at 1- and 5-years [11]. The data presented here does not reflect such a high 1-year survival for HEH patients after
LT, but the 5-year survival is markedly improved. Rodriguez et al. also looked at the UNOS/OPTN database for HEH alone, and found the same 1- and 5-year survivals from 1997-2005 [10]. Comparatively, a study of the European Liver Transplant Registry analyzed 59 patients and their survival outcomes after LT. 93% and 83% at 1- and 5-years post-transplant, finding nodal invasion and extrahepatic disease did not significantly affect outcome [25]. A study of the Mayo Clinic retrospectively reviewed 30 patients with HEH who underwent liver resection, LT, chemotherapy or no therapy and found liver resection to be a comparable option for surgical treatment compared to LT when allowing for patient selection [26]. Similar to Mehrabi et al.’s review, liver resection (Lrx) candidates had better survival outcomes; this is possibly attributed to a lower stage at presentation. Mehrabi et al.’s group reported 27 patients who had Lrx, only 9.4% of the sample size compared to 44.8% who underwent LT. Lrx patients are likely healthier with less of a tumor burden at presentation and presumably, a better prognosis. Until further prospective, multi-center trials are performed, LT remains a viable treatment option for a large portion of HEH patients, with excellent outcomes reported in this study.

Cholangiocarcinoma patients transplanted in the past 16 years had poorer outcomes, significantly so when compared to the cohort with HCC and HEH. A recent Cochrane review of the literature reports a 39% pooled survival rate by 5-years, concordant with this study’s findings [27]. Recently, cholangiocarcinoma treatment has evolved to include neoadjuvant chemoradiation therapy, yielding a 5-year survival rate of 73% from a prospective cohort of 120 patients [6]. Another smaller series of cholangiocarcinoma patients performed by Punjala et al. studied the effects of neoadjuvant chemoradiation therapy prior to LT on a cohort of 22 patients and found significant improvement in projected survival [27]. Gu et al.’s meta-analysis found the reports integrating preoperative adjuvant therapies had improved (survival at 5-years to 65%). As the future brings improved adjuvant therapies, undoubtedly predicted survival rates for this disease will increase over time.

Hepatic sarcomas of the liver are not often transplanted in the US, as reflected by the small sample size in this study. The predicted survivals found in this report show a trend similarly poor compared to cholangiocarcinoma patients, though without statistical significance, it is difficult to draw conclusions. Both primary and metastatic sarcomas of the liver have, in limited series and of varying histologies, proven to have prohibitive outcomes in general. A small prospective study done in Germany did find a 65% survival rate at 5-years in their cohort of 22 patients, finding histology was a significant factor in prognosis [28]. Currently, however, hepatic sarcoma is not a diagnosis eligible for transplantation in the US, in large part due to the dismal outcomes reflected in this study and in recent literature [29-31].

Combined HCC-CC patients fared the worst when compared to all the primary liver tumors studied, significantly so when compared to HCC and HEH. Other studies have shown HCC-CC also fare worse when compared to cholangiocarcinoma alone, though this analysis did not show this trend to be statistically significant [1,5,6,32]. When this subgroup was compared to all LTs performed for the indication of a primary liver tumor, HCC-CC continued to have a dismal prognosis, significantly so in terms of overall patient and allograft survival.

HCC-CC is a rare malignancy comprised of histopathological features of both hepatocellular carcinoma and cholangiocarcinoma [33]. Preoperative diagnosis is difficult, and in fact, most patients are misdiagnosed as having HCC or cholangiocarcinoma [14,34]. In the UNOS/OPTN database, diagnosis entered is made preoperatively and is the indication for listing and transplantation. Index of suspicion for HCC-CC may be raised with increased CA 19-9, Alpha-fetoprotein serum levels and imaging studies, prompting biopsies and ductal brushings, though often pathological diagnosis is confirmed after LT [15,34]. Hepatic resection with hilar lymph node dissection is the surgical treatment of choice when preoperative diagnosis is made. An Italian study in 2008 found 18 patients with combined HCC-CC who had disease-specific survival to be 90.9%, 62.3% and 62.3% at 1-, 3- and 5-year survival after hepatic resection, with hilar nodal resection for 8 of those patients [12]. The role of LT for HCC-CC, on the other hand, is still controversial, with data lacking of outcomes and results [15,35,36]. One study analyzed the SEER registry to find whether cancer-directed therapies changed survival outcomes. Of 380 patients with HCC-CC, 20 received LT as their cancer-directed therapy and analysis proved transplantation did indeed correlate with improved outcomes compared to those who did not receive cancer-directed treatment [20]. Here, we are able to identify a dozen cases documented to have undergone liver transplantation with the diagnosis of HCC-CC in the United States with long-term follow-up. For this analysis, LT for HCC-CC does not offer hopeful prospects relative to all other primary tumors of the liver, and warrants further investigation.

In using the UNOS/OPTN dataset to assess outcomes, there are limitations which deserve acknowledgement. Regrettably, this database does not contain certain specific clinical data, including location of
primary liver tumors which has implications for management and outcomes. Tumor stage at initial presentation is unknown, as well as final pathological staging and time of diagnosis, which may underrepresent the actual number of cancer cases present in the transplant population. Treatment, preoperatively and postoperatively, are not recorded, and neither are tumor markers and histological signs which have been shown to influence recurrence and survival, including CA 19-9, vascular invasion, tumor size, location and multiplicity [14,15]. This makes comparisons between stages and standardization of care challenging.

However, the survival curves we report here represent overall outcomes of primary liver tumors which continue to be important, both in patient education, organ allocation and post-transplant care. This data illustrates outcomes of current transplant management for primary liver tumors. Rather than deriving from a single institution’s experience, information is gathered on outcomes of a national experience, increasing the sample size and power of the results, which on rare diseases would be otherwise difficult to describe. The values reported here serve as salient pieces of data to the informed transplant team and transplant patient, as part of their clinical care and decision-making.

Although survival outcomes after transplantation with more common tumors have been well established, our findings suggest that patients undergoing LT for HEH also carry acceptable outcomes, but that for patients with combined HCC-CC, LT may not be an ideal treatment alone. Other forms of adjuvant and neoadjuvant therapy may be indicated for these patients. Patients with cholangiocarcinoma may have poorer outcomes after LT, though recent changes in adjuvant therapy and medical management may improve survival.

References


